[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017009671A2 - inibidores de ezh2 e usos destes - Google Patents

inibidores de ezh2 e usos destes

Info

Publication number
BR112017009671A2
BR112017009671A2 BR112017009671A BR112017009671A BR112017009671A2 BR 112017009671 A2 BR112017009671 A2 BR 112017009671A2 BR 112017009671 A BR112017009671 A BR 112017009671A BR 112017009671 A BR112017009671 A BR 112017009671A BR 112017009671 A2 BR112017009671 A2 BR 112017009671A2
Authority
BR
Brazil
Prior art keywords
ezh2
inhibitors
ezh1
homologous
methods
Prior art date
Application number
BR112017009671A
Other languages
English (en)
Inventor
E Bradner James
Qi Jun
Kin Wong Kwok
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR112017009671A2 publication Critical patent/BR112017009671A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente descrição proporciona compostos de qualquer uma das fórmulas (i) e (ii). os compostos aqui descritos são inibidores de histonas metiltransferases (e.g., potenciador de zeste homólogo 1 (ezh1) e intensificador de zeste homólogo 2 (ezh2)) são úteis no tratamento e / ou prevenção de uma ampla gama de doenças (por exemplo, doenças proliferativas). a presente invenção também fornece composições farmacêuticas, kits, métodos, e usos incluindo ou usando um composto descrito aqui. ademais, também é fornecido são métodos de identificação de inibidores de ezh1 e/ou ezh2. (i) (ii)
BR112017009671A 2014-11-06 2015-11-06 inibidores de ezh2 e usos destes BR112017009671A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076410P 2014-11-06 2014-11-06
PCT/US2015/059622 WO2016073956A1 (en) 2014-11-06 2015-11-06 Ezh2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112017009671A2 true BR112017009671A2 (pt) 2017-12-26

Family

ID=55909933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009671A BR112017009671A2 (pt) 2014-11-06 2015-11-06 inibidores de ezh2 e usos destes

Country Status (8)

Country Link
US (1) US11236082B2 (pt)
EP (2) EP3885343A1 (pt)
KR (1) KR20170081213A (pt)
CN (2) CN107105651A (pt)
AU (1) AU2015342774C1 (pt)
BR (1) BR112017009671A2 (pt)
CA (1) CA2964629A1 (pt)
WO (1) WO2016073956A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11819554B2 (en) * 2015-09-17 2023-11-21 University Of Massachusetts Compositions and methods for modulating FMR1 expression
CA3018270A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
WO2018076060A1 (en) 2016-10-26 2018-05-03 Genea Ip Holdings Pty Ltd Improved generation of muscle lineage cells and therapeutic uses thereof
SG10202104386UA (en) * 2016-10-28 2021-05-28 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
WO2018089772A1 (en) * 2016-11-10 2018-05-17 Memorial Sloan-Kettering Cancer Center Inhibition of kmt2d for the treatment of cancer
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
KR20190105602A (ko) 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
JP2021500326A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
EA202090955A1 (ru) * 2017-10-18 2020-11-27 Эпизайм, Инк. Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
PT4043466T (pt) 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
CN109966479A (zh) * 2019-02-26 2019-07-05 上海长征医院 Ezh2在制备预防或治疗多囊肾病药物中的应用
WO2020247130A1 (en) * 2019-06-03 2020-12-10 Icahn School Of Medicine At Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN112341390B (zh) * 2019-08-07 2022-08-23 四川大学 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
EP3797777A1 (en) 2019-09-30 2021-03-31 Eberhard Karls Universität Tübingen Medizinische Fakultät Agent for the treatment of psoriasis
CN111303133A (zh) * 2020-03-25 2020-06-19 清华大学 降解ezh2蛋白的小分子化合物
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2022042527A1 (zh) * 2020-08-24 2022-03-03 北京大学 治疗内耳及肠道上皮组织损伤相关疾病的小分子药物
CN112715484B (zh) * 2020-12-29 2022-04-22 四川省人民医院 构建视网膜色素变性疾病模型的方法、应用以及繁育方法
CN114028397A (zh) * 2021-02-01 2022-02-11 徐州医科大学 Gsk126作为ezh2抑制剂在制备预防和/或治疗缺血性脑卒中药物中的应用
US20230054313A1 (en) * 2021-07-16 2023-02-23 University Of North Texas Antithrombotic compositions and methods for using same
CN113736728B (zh) * 2021-08-20 2024-03-08 内蒙古大学 一种小鼠体细胞核移植胚胎培养液及胚胎培养方法
CN119095624A (zh) 2022-04-27 2024-12-06 第一三共株式会社 抗体-药物缀合物与ezh1和/或ezh2抑制剂的组合
GB202218325D0 (en) * 2022-12-06 2023-01-18 Univ Cape Town Phenyl-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivates for use as 5-alpha reductase antagonists in methods of treatment
CN118240776B (zh) * 2024-05-29 2024-08-23 上海凌医生物科技有限公司 一种提高aav病毒产量的方法
CN118702679B (zh) * 2024-08-26 2024-10-29 四川大学华西医院 一种具有ezh2/brd4双靶点活性的化合物、药物组合物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658649A (en) 1985-06-06 1987-04-21 Combustion Engineering, Inc. Ultrasonic method and device for detecting and measuring defects in metal media
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
WO2010008436A1 (en) 2008-06-24 2010-01-21 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for inhibition of bcl6 repression
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
LT2566327T (lt) * 2010-05-07 2017-05-25 Glaxosmithkline Llc Indolai
CN103037865B (zh) 2010-05-14 2014-10-29 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的化合物
US20120014979A1 (en) 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2681216B1 (en) * 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
ES2624986T3 (es) * 2011-09-13 2017-07-18 Glaxosmithkline Llc Azaindazoles
WO2013049770A2 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
RU2621148C2 (ru) * 2011-11-04 2017-05-31 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Способ лечения
ES2970401T3 (es) 2012-02-17 2024-05-28 Ansun Biopharma Inc Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza
EP2825161B1 (en) 2012-03-12 2019-01-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
SG10201912111TA (en) 2012-04-13 2020-02-27 Epizyme Inc Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
WO2014100665A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
BR112017009440A2 (pt) 2014-11-06 2017-12-19 Dana Farber Cancer Inst Inc uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
CA3018270A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2964629A1 (en) 2016-05-12
AU2015342774B2 (en) 2020-01-30
AU2015342774A1 (en) 2017-04-27
EP3214935A1 (en) 2017-09-13
AU2015342774C1 (en) 2021-08-05
EP3214935A4 (en) 2018-08-29
CN113444086A (zh) 2021-09-28
KR20170081213A (ko) 2017-07-11
CN107105651A (zh) 2017-08-29
US20180297993A1 (en) 2018-10-18
US11236082B2 (en) 2022-02-01
EP3885343A1 (en) 2021-09-29
CN113444086B (zh) 2024-04-30
WO2016073956A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
BR112016028255A2 (pt) agentes imunorreguladores
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201790108A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201790806A1 (ru) Иммунорегулирующие средства
EA201790992A1 (ru) Иммунорегуляторные агенты
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
EA201691134A1 (ru) Новые ингибиторы глутаминазы
BR112016029846A2 (pt) ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo?
ZA201904522B (en) Heterocyclic inhibitors of mct4
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
CY1122364T1 (el) Αναστολεις της ezh2
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]